3Tomoyuki Imagawa,Masaaki Mori,Takako Miyamae,Shuichi Ito,Tomoko Nakamura,Kiyoshi Yasui,Hirokazu Kimura,Shumpei Yokota. Plasma exchange for refractory Kawasaki disease[J] 2004,European Journal of Pediatrics(4-5):263～264
二级参考文献12
1Kritvikrom D, Vymutt J, Gururaj, JM, et al. The Prevention of Coronary artery aneurysm in Kawasaki disease: a meta - analysis on the efficacy of aspirin and immunoglobulin treatment[J ]. Pediatrics, 1995, 96:105 - 107.
2Durongpisitkul K. Soongswang J, Laohaprasitiorn D, et al. Immunoglobulin faiure and retreatment in Kawasaki diseases[ J ]. Pediatr Cardiol, 2003,24:145 - 148.
3Sundel RP, Burns JC, Baker A, et al. Gamma globulin re - treat ment in Kawasaki disease[J]. Pediatr, 1993, 123:657- 659.
4Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin- resistant Kawasaki disease with pulsed doses of corticosteroids[ J ]. Pediatr, 1996,128:146 - 149.
5Takagi N, Kihara M, Yamaguchi S, et al. Plasma exchange in Kawasaki disease[J]. Lancet, 1995, 346:1307.
7Furusho K, Kamiya T, Nakano H, et al. High - dose intravenous gammaglobulin for Kawasaki disease[ J ]. Lancet, 1984,2:1055 -1058.
8Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gammaglobulin as compared with four infusions in the treatment of acute Kawasaki syndrome[J]. N Engl J Med,1991,324 : 1633 - 1639.
9Fukunishi M, Kikkswa M, Hamana K, et al. Prediction of nonresponsiveness to intravenous high - dose gammaglobulin therapy in patients with Kawasaki disease at onset [ J ]. J Pediatr, 1999,137:172- 175.
10Khowsathit P, Hong - Hgam C, Khositseth A, Wanitkun S.Treatment of Kawasaki disease with a moderate dose (1g/kg) of intravenous immunoglobulin[J ]. J Med Assoc Thai, 2002, Nov,85 Suppl 4:S1121 - 1126.
4Jang G C,Kim H Y,Ahn S Y,et al. Raised Serum lnterleukin 15 Levels in Kawasaki Disease[J]. Ann Rheum Dis, 2003,62 (3) ,264-266.
5Newburger J W, Takahashi M, Gerber M A, et al. Diagnosis, Treatment,and Long-term Management of Kawasaki Disease:a Statement for Health Professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart[J]. Circulation, 2004,110 ( 17 ) : 2747-2771.
6Falcini F. Kawasaki Disease[J]. Curr Opin Rheumatol,2006,18 (1),33-38.
7Yeung R S. Pathogenesis and Treatment of Kawasaki's Disease [J]. Curr Opin Rheumatol,2005,17(5) : 617-623.
8Sorbera L A. Procalcitonin as an Effective Biomarker for the Diagnosis and Prognosis of Severe Sepsis. Highlights form the25th International Symposium on Intensive Care and Emergency Medicine. March 21 - 25,2005, Brussels, Belgium[J]. Drugs Today(Bare), 2005,41 ( 4 ) : 253-256.
9Okada Y, Minakami H, Tomomasa T, et al. Serum Procalcitonin Concectration in Patients with Kawasaki Disease[J].J Infect,2004,48(2) :199-205.
10Meisner M. Pathobiochemistry and Clinical Use of Procalcitonin[J]. Clin Chim Acta,2002,323(1/2) :17-29.
